Deliver logo
Program Overview
The Asia Pharma R&D Leaders Summit 2020 ( ‘ APRDL 2020 ‘ ) will bring in fresh perspectives and establish an efficient platform to discuss about the Trends for Future Global Pharma R&D Revolution and Promoting China Innovation: Emerging Therapeutics Research Innovation and Effective Partnership Model; Promoting China Innovation and Regulatory Landscape; Cellular-Based Immunotherapies ( CAR-T & TCR-T Cell Therapy, CAR-NK, TIL Therapy, iPSC-derived Cell Therapy & Gene-Edited Cell Therapies etc., ); AAV-Based Gene Therapy for Human Diseases; Stem Cell-based Therapies and Regenerative Medicine Development for CNS, Diabetes and Anti-Heart Failure; Advancing Treatment for NASH & Liver Diseases; siRNA Therapeutic; Immuno-Oncology Drug Development and CMO-MAH Integration; Computer-Accelerate Rational Discovery (CARD); Strengthening Pharma R&D Collaboration; Artificial Intelligence Innovation in Drug Discovery and Development; IP Patent Strategies and Funding Investment Opportunities; New Formulation and Process Development, API Manufacturing, Analytical Operations, Genotoxic Impurities in Pharmaceuticals, Best Practices & BE Study of Generic Drugs; Drug Delivery and Formulation Development etc.,

Brainstorm with over 100+ high caliber speakers and estimation to bring over 500+ Industry Stakeholders, Entrepreneurs, Influencers and Pharma R&D professionals, With this in mind, The Themes of “ Asia Pharma R&D Leaders Summit 2020 “ will cover:

Part A: Gene & Cellular Immunotherapy Revolution
-- The CAR-T Cell Revolution -- CAR T-Cell Therapy targeting Leukemia, Lymphoma, and Future Hopes for Solid Tumors
-- Engineering TCR-based Cell Immunotherapy against Cancer and Viral Infection
-- Developing AAV-based Gene Therapy Products in China
-- A Broad Technology Platform for Reprogramming, Expansion of Pluripotent Stem Cells and Differentiation to Cell & Gene Therapies
-- Precision Immunotherapy: Development BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma
-- Solid Tumor CAR-T Barriers and Solutions
-- Development of Next Generation Safe and Potent NKG2D CAR-T Cell Therapy and Next Generation CAR-T Cells
-- Non-Viral CAR-T Cell Therapy for Tumor
-- The Latest Advancement in T-cell-based Cancer Immunotherapy
-- Challenges and Prospects of Allogeneic CAR-T Cell Therapy
-- Advancing Cancer Adoptive Immunotherapy with CRISPR/Cas9 Gene Edited T cells
-- CAR-T Cell Therapy Translational Insights: Correlates of Toxicity, Safety & Efficacy
-- The State of the ART of Manufacturing CAR T Cells and The Latest Advancements
-- Developing Allogeneic Cancer Immunotherapy with iPSC Technology
-- Cell Therapy Manufacturing Commercialization - Strategy and Challenges
-- Automated Manufacturing of Chimeric Antigen Receptor T Cells
-- T-Cell Therapy Manufacturing, Bioprocessing and Commercialization
-- Revolution of CAR-T Cell Therapies: Regulatory and Commercialization Considerations
-- Building a Cell Therapy Platform Company to Develop Best in Class Products in China
-- Treating solid tumors with TCR-mimic antibody redirected ARTEMISTM T-cells
-- Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors
-- Clinical Development of CAR T cell Therapy and Next Generation CAR T cells
-- Flow Cytometry Do for CAR-T

Part B: Future Cancer Immunotherapy Revolution; SiRNA Therapeutics & Drug Development; Strengthening Pharma R&D Collaboration
-- Development and Commercialization of Globally Innovative Medicines in China
-- Advancing siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint Inhibitor
-- Cancer Immunotherapy: Opportunity and Challenge
-- Future Cancer Immunotherapy Revolution
-- Novel Business Model and Biomarker Platform for Developing First-in-Class Drugs Globally with Targeted Precision Medicine
-- Small Molecule, Big Impact – Targeting Synthetic lethality for Anticancer Therapy
-- Accelerating Oncology Drug Development in China: How best to address important unmet needs in China with an integrated local development strategy
-- New Modalities Research Opportunities and Innovative Collaboration Model in China
-- The aftermath of COVID-19: How will this affect Global and China Pharma R&D Industry
-- Computer-accelerate rational discovery (CARD) -- 计算机加速药物创新的策略和愿景
-- Growth in Quality of Innovation – Innovative Drug Discovery in China

Part C: 新药研发到商业化生产: 原料药工艺开发; CMC的挑战和策略; MAH实践
-- 早期临床用药生产及原料药及制剂药学研究
-- 商业化制剂设计, 研发与中试放大, 技术及法规要求
-- 原料药工业生产中的杂质控制与系统研究
-- 新药创新中的原料药工艺开发
-- CMC的挑战和策略, 处方工艺设计
-- 原辅料物化特性对合理的产品设计, 开发与中试放大的影响
-- 原料药的开发, 质量控制及未来发展趋势
-- 原料药工艺合成及工艺路线优化
-- 临床药品的生产放大及技术转移
-- 从新药研发到商业化生产-产业化项目以及MAH实践
-- MAH制度赋能新药研发
-- 促进源于中国的创新: 汇聚中国制药产业“源动力”-- 我国原料药产业发展现状与趋势

Part D: 质谱分析法; 基因毒性和元素杂质控制; 创新制剂设计与开发; 注射剂一致性评价; 溶出度试验技术
-- Application of multi-stage mass spectrometry (MSn) in solving challenging problems in pharmaceutical industry: from rapid structure elucidation, drug degradation mechanism studies, to detection of genotoxic impurities
-- 基因毒性杂质和元素杂质控制策略与分析方法
-- 注射剂一致性评价&焦点问题
-- 口服固体制剂开发思路与策略
-- 口服固体制剂溶出度试验技术探讨-溶出度和溶出曲线
-- 吸入制剂颗粒处理工艺及制剂特性相关颗粒性质评价
-- 长效和靶向微球制剂工业开发及质量控制
-- 注射剂一致性评价开发以及制剂处方工艺开发及临床评价关键技术以及相关焦点问题探讨
Asia Pharma R&D Leaders Summit 2020  |  Telephone: +86 21 6157 7321  |  E-mail: kevin.tan@deliver-consulting.com
© 2020 Asia Pharma R&D Leaders Summit 2020- All rights reserved